T. Rowe Price Associates’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

T. Rowe Price Associates’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-63,047	Closed	-$398K	–	2984
2022 Q4	$398K	Hold	63,047	–	–	﹤0.01%	2244
2022 Q3	$323K	Sell	63,047 -546,607	-90%	-$3.43M	﹤0.01%	2344
2022 Q2	$3.82M	Sell	609,654 -179,936	-23%	-$606K	﹤0.01%	1461
2022 Q1	$2.8M	Sell	789,590 -68,505	-8%	-$253K	﹤0.01%	1585
2021 Q4	$4.31M	Buy	858,095 +34,713	+4%	+$209K	﹤0.01%	1514
2021 Q3	$6.03M	Sell	823,382 -4,346	-0.5%	-$29.8K	﹤0.01%	1491
2021 Q2	$7.11M	Buy	+827,728	New	+$7.06M	﹤0.01%	1459

T. Rowe Price Associates's FSTX Position: Q1 2023 in Review

T. Rowe Price Associates sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 63,047 shares — an estimated $398K sold.

T. Rowe Price Associates first reported a position in FSTX in Q2 2021 and held it in 7 quarters. The position peaked at $7.11M in Q2 2021. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

T. Rowe Price Associates reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
T. Rowe Price Associates sold 63,047 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $398K.
T. Rowe Price Associates first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2021 and held it in 7 quarters.
T. Rowe Price Associates's F-star Therapeutics, Inc. Common Stock position peaked at $7.11M in Q2 2021.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.